Intercept shows another significant benefit of Ocaliva to people with PCB

New York-based biotech company Intercept Pharmaceuticals keeps momentum: its shares have risen over 15% since the beginning of the month. Intercept yesterday announced in a press release that the Phase III POISE clinical trial has demonstrated that Ocaliva (obeticholic acid) cures fibrosis and cirrhosis in patients with primary biliary cholangitis (PCB). A complete data analysis will be presented at the International Liver Congress 2018, to be held in Paris from April 11th to 15th.

(Source: Intercept)